Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.45 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)442.26K
Market Cap
$335.20M
Enterprise Value$99.81M
Total Cash (Recent Filing)$66.26M
Total Debt (Recent Filing)$73.15M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 07, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding32,798,504
10 Day Avg. Volume537,606
30 Day Avg. Volume442,261
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.98
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$17.67Price Target Upside72.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
NeuroPace News
PremiumCompany Announcements
NeuroPace Appoints New CFO Amid Strategic ShiftPremiumCompany Announcements
NeuroPace Holds Virtual Annual Stockholders MeetingPremiumCompany Announcements
NeuroPace Secures $75 Million Credit Facility with MidCap
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNPCE announced the refinancing of its $60mn term loan at much more attractive terms, reducing annual cash burn by ~$3.5mn.
Growth PotentialManagement expects to have over 20% CAGR through 2027.
Regulatory ProspectsNPCE has a solid case to support FDA approval in IGE based on the totality of the NAUTILUS data.
Bears Say
Clinical Trial ResultsThe study did not show statistical significance on its primary efficacy endpoint at 1-year follow-up.
Price Target AdjustmentAnalyst decreases the price target for NPCE from $18 to $16.
Regulatory RiskThe NAUTILUS announcement creates additional near-term regulatory risk for the company.
Ownership Overview
42.42% Insiders
5.40% Mutual Funds
17.78% Other Institutional Investors
22.66% Public Companies and Individual Investors
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $5.45 and its highest was $18.98 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $335.20M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is Aug 07, 2025 which is in 29 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on May 13, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.241 by $0.031.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.22.
How many shares outstanding does NeuroPace have?
NeuroPace has 32,798,504 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.241. Following the earnings report the stock price went up 20.463%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (72.90% Upside)
$17.67 (72.90% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.16%
12-Months-Change
Fundamentals
Return on Equity
-128.49%
Trailing 12-Months
Asset Growth
11.48%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the RNS System and improvements in gross margin, alongside successful equity financing and positive clinical results. However, there were challenges with increased R&D expenses and the decision to terminate SEEG product distribution. Overall, the highlights significantly outweigh the lowlights, indicating a positive outlook.Read More>NPCE Stock 12 Month Forecast
Average Price Target
$17.67
▲(72.90%Upside)